Brief: Oxford Cannabinoid Technologies To Review Allocation Of Its Existing Budget

Oxford Cannabinoid Technologies Holdings

26/08/2022 07:12

Aug 26 (Reuters) - Oxford Cannabinoid Technologies Holdings
PLC  OCTP.L :
    * OXFORD CANNABINOID  - STRATEGIC BUDGET REVIEW &
DIRECTORATE
CHANGE
    * OXFORD CANNABINOID TECHNOLOGIES - BOARD CONSIDERS IT
PRUDENT TO
TEMPORARILY DELAY PHASE I CLINICAL TRIALS OF OCT130401, ITS
SECOND PROGRAMME
    * OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC - PHASE I
CLINICAL
TRIALS FOR COMPANY'S LEAD PROGRAMME, OCT461201 REMAIN ON TRACK
    * OXFORD CANNABINOID TECHNOLOGIES - EXISTING FUNDS, WHICH
WOULD
OTHERWISE HAVE BEEN FULLY UTILISED BY APRIL 2023, WILL NOW
EXTEND TO Q4 2023
    * OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC -
PRE-CLINICAL WORK
FOR OCT130401 WILL CONTINUE
    * OXFORD CANNABINOID TECHNOLOGIES - KAREN LOWE, CURRENTLY
GROUP
FINANCE DIRECTOR, HAS INFORMED BOARD OF HER WISH TO STEP DOWN
    * OXFORD CANNABINOID TECH. HOLDINGS - BOARD TO REVIEW
ALLOCATION
OF ITS EXISTING BUDGET

Source text for Eikon:  ID:nRSZ3472Xa 
Further company coverage:  OCTP.L 

 ((Reuters.Briefs@thomsonreuters.com;;))